The 36-month beta value for QNCX is also noteworthy at 1.04. There are mixed opinions on the stock, with 1 analysts rating it as a “buy”, 0 rating it as “overweight”, 4 rating it as “hold”, and 0 rating it as “sell”.
The public float for QNCX is 48.34M, and at present, short sellers hold a 3.88% of that float. The average trading volume of QNCX on February 12, 2026 was 28.63M shares.
QNCX stock’s latest price update
The stock of Quince Therapeutics Inc (NASDAQ: QNCX) has increased by 15.60% when compared to last closing price of $0.53.Despite this, the company has seen a gain of 283.89% in its stock price over the last five trading days. feeds.benzinga.com reported 2026-02-10 that Quince Therapeutics Inc shares are soaring Tuesday as the company has engaged LifeSci Capital to serve as its exclusive financial advisor.
QNCX’s Market Performance
Quince Therapeutics Inc (QNCX) has experienced a 283.89% rise in stock performance for the past week, with a -79.32% drop in the past month, and a -61.88% drop in the past quarter. The volatility ratio for the week is 57.89%, and the volatility levels for the past 30 days are at 85.64% for QNCX. The simple moving average for the past 20 days is -64.51% for QNCX’s stock, with a -67.53% simple moving average for the past 200 days.
Analysts’ Opinion of QNCX
Citizens JMP, on the other hand, stated in their research note that they expect to see QNCX reach a price target of $9. The rating they have provided for QNCX stocks is “Mkt Outperform” according to the report published on August 05th, 2025.
QNCX Trading at -77.91% from the 50-Day Moving Average
After a stumble in the market that brought QNCX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.59% of loss for the given period.
Volatility was left at 85.64%, however, over the last 30 days, the volatility rate increased by 57.89%.
Insider Trading
Benatti Luca, the Director of Quince Therapeutics Inc, sale 50,000 shares at $3.47 during a trade that took place back on Dec 26 ’25, which means that Benatti Luca is holding 39,179 shares at $173,500 based on the most recent closing price.
Stock Fundamentals for QNCX
The total capital return value is set at -0.55%. Equity return is now at value -247.78%, with -48.20% for asset returns.
Based on Quince Therapeutics Inc (QNCX), the company’s capital structure generated 0.94 points at debt to capital in total, while cash flow to debt ratio is standing at -2.14.
Currently, EBITDA for the company is -$35.98 million with net debt to EBITDA at -0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.12.
Conclusion
In summary, Quince Therapeutics Inc (QNCX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.